“Corona Delta” besieges Pfizer… Unreassuring news!

0
28


It was not long before the first year of the Corona epidemic passed and the world was reassured about the continuation of vaccination campaigns, until the virus mutated and began to evade, and while Pfizer reassured its audience that its product is effective even against mutations, a joint British-American study found that the levels of antibodies in the blood of people who They were vaccinated with the “Pfizer-Biontech” vaccine, which is able to recognize the novel coronavirus “delta” variant (B.1.617.2), which was first discovered in India, on average less than those capable of recognizing the variants Previously traded in the UK.

The results also indicated that the levels of these antibodies are lower with age, and that levels decrease over time, which provides additional evidence to support plans to provide vaccination to people at risk in the fall, according to a study published by “The Lancet”, in which the Francis Crick Institute participated. in London, the National Institute for Health Research NIHR in Britain, and the Biomedical Research Center at the University of California, USA.

However, recent results support current plans to reduce the dose gap between vaccines, because they found that after only one dose of the Pfizer-Biontech vaccine, people are less likely to develop antibody levels against the new “delta” variant, versus the “alpha” variant or What is known as (B.1.1.7) previously prevailing.

Antibodies alone are not enough

Although these results are necessary to provide evidence about how the virus evolved to escape from the first generation of vaccines, antibody levels alone do not predict the efficacy of the vaccine, but more comprehensive studies are also needed, where low neutralizing antibody levels remain associated with protection against corona.

In addition, these findings are the largest published study to date looking at the ability of vaccine-induced antibodies to neutralize the latest worrisome variants in healthy adults.

The researchers have submitted their findings to the National Consortium for Genotype-to-Phenotype Virology (G2P-UK), the New and Emerging Respiratory Threats Advisory Group (NERVTAG) and the Joint Committee on Vaccination and Immunization (JCVI), as evidence of the level of protection people may receive from variants. The new one after one dose and after two doses of Pfizer vaccine.

Really less

Healthcare workers and staff from the Francis Crick Institute, the National Institute for Health Research, and the University of California’s Biomedical Research Center regularly donated blood samples and swabs as part of the study, so they could track changing infection risks and response to vaccination.

With samples of the most recent variables of concern presented, the researchers were able to quickly assess the potential risks that these variables might pose.

And within a few days, they were able to get enough of each study variable, analyzing the antibodies in the blood of 250 healthy people who received either one or two doses of the Pfizer-Biontech vaccine, up to 3 months after they took the first dose, testing the ability of the antibodies to prevent The entry of the virus into cells, through the so-called “neutralizing antibodies”, in the presence of five different variants of the virus, which is the original strain that was first discovered in Wuhan, China, and the dominant strain in Europe during the first wave in April 2020 (D614G), And the variable “alpha” or (B.1.1.7), which was discovered in the United Kingdom, and the variant “beta” or what is known (B.1.351), which was first discovered in South Africa, and the variant “delta” or (B. 1.617.2).

Until data from previous clinical studies indicated that higher antibody titers – the highest dilution level still prevented 50% of virus infection in the laboratory, which is a good indicator of vaccine efficacy and greater protection against corona.

They also found that in people fully vaccinated with two doses of the Pfizer Bionic vaccine, neutralizing antibody levels were five times lower against the delta variant compared to the original strain, on which current vaccines are based. Importantly, the antibody response was lower in people who received only one dose.

Watch out for the upcoming period

In addition, Emma Wall, an infectious disease consultant at the University of California, Los Angeles, and the researcher involved in the study explained in a report published by the Francis Crick Institute on June 4, that it is likely that this virus will be present for some time in the future, so we need Until we remain vigilant, our study is designed to be responsive to shifts in the epidemic so that we can quickly provide evidence of this.

It is worth noting that Pfizer and Biontech have been busy over the past months in testing their vaccines on children, after they found in March that the Corona virus vaccine was 100% effective for children aged 12 to 15 years, in a clinical trial on more than 2,000 adolescents. .

It was discovered that the vaccine generates strong antibody responses.

");
//},3000);
}
});
//$(window).bind('scroll');
$(window).scroll(function () {
if (alreadyLoaded_facebookConnect == false) {
alreadyLoaded_facebookConnect = true;
// $(window).unbind('scroll');
// console.log(" scroll loaded");

(function (d, s, id) {
var js, fjs = d.getElementsByTagName(s)[0];
if (d.getElementById(id)) return;
js = d.createElement(s); js.id = id;
js.async = true;
js._https = true;
js.src = "https://connect.facebook.net/en_US/all.js#xfbml=1&appId=148379388602322";
fjs.parentNode.insertBefore(js, fjs);
}(document, 'script', 'facebook-jssdk'));
// pre_loader();
// $(window).unbind('mousemove');
//setTimeout(function(){
// $('#boxTwitter').html("");
//},3000);

var scriptTag = document.createElement("script");
scriptTag.type = "text/javascript"
scriptTag.src = "https://news.google.com/scripts/social.js";
scriptTag.async = true;
document.getElementsByTagName("head")[0].appendChild(scriptTag);

(function () {
$.getScript("https://news.google.com/scripts/social.js", function () { });
});

}
});

//$(window).load(function () {
// setTimeout(function(){
// // add the returned content to a newly created script tag
// var se = document.createElement('script');
// se.type = "text/javascript";
// //se.async = true;
// se.text = "setTimeout(function(){ pre_loader(); },5000); ";
// document.getElementsByTagName('body')[0].appendChild(se);
// },5000);
//});





LEAVE A REPLY

Please enter your comment!
Please enter your name here